JGP Global Gestao de Recursos Ltda. acquired a new stake in shares of Epizyme, Inc. (NASDAQ:EPZM) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 15,333 shares of the biopharmaceutical company’s stock, valued at approximately $292,000. Epizyme makes up about 0.3% of JGP Global Gestao de Recursos Ltda.’s investment portfolio, making the stock its 22nd biggest position.

Other hedge funds and other institutional investors have also modified their holdings of the company. Legal & General Group Plc grew its stake in Epizyme by 8.9% during the 1st quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 795 shares in the last quarter. UBS Asset Management Americas Inc. acquired a new stake in Epizyme during the 1st quarter valued at approximately $175,000. BB&T Securities LLC acquired a new stake in Epizyme during the 2nd quarter valued at approximately $181,000. Trexquant Investment LP acquired a new stake in Epizyme during the 2nd quarter valued at approximately $184,000. Finally, SG Americas Securities LLC grew its stake in Epizyme by 83.3% during the 2nd quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 6,072 shares in the last quarter. Hedge funds and other institutional investors own 78.00% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “JGP Global Gestao de Recursos Ltda. Acquires New Position in Epizyme, Inc. (EPZM)” was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/jgp-global-gestao-de-recursos-ltda-acquires-new-position-in-epizyme-inc-epzm/1723067.html.

Several research analysts have recently commented on EPZM shares. HC Wainwright reiterated a “buy” rating on shares of Epizyme in a research report on Monday, August 7th. Royal Bank Of Canada set a $20.00 target price on Epizyme and gave the stock a “buy” rating in a research report on Saturday, August 5th. Cann reiterated a “buy” rating and issued a $26.00 target price on shares of Epizyme in a research report on Thursday, November 2nd. Zacks Investment Research upgraded Epizyme from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research report on Monday, October 16th. Finally, Jefferies Group LLC started coverage on Epizyme in a research report on Wednesday, September 20th. They issued a “buy” rating and a $23.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $22.67.

In related news, Director David M. Mott purchased 200,000 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The shares were acquired at an average price of $15.25 per share, with a total value of $3,050,000.00. Following the acquisition, the director now owns 6,000 shares in the company, valued at approximately $91,500. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $16.44, for a total value of $246,600.00. Following the completion of the sale, the insider now directly owns 23,123 shares in the company, valued at approximately $380,142.12. The disclosure for this sale can be found here. Company insiders own 25.20% of the company’s stock.

Epizyme, Inc. (NASDAQ:EPZM) opened at $12.70 on Friday. Epizyme, Inc. has a 12-month low of $9.30 and a 12-month high of $20.45.

Epizyme (NASDAQ:EPZM) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.02. equities research analysts anticipate that Epizyme, Inc. will post -2.23 EPS for the current fiscal year.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.